Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 15 Show results per page	View Search Criteria \| Help With Results


1.		Phase III Compazine vs Methadone vs Tetrahydrocannabinol vs Placebo in Patients Receiving ADR for Malignant Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care				Completed				no age specified								MAYO-818304 NCCTG-818304, NCI-W82-1092, W82-1092

Last Modified: 12/4/2006 First Published: 7/1/2001


2.		Phase III Randomized Study of 3 Regimens For the Prevention of Delayed Nausea After Chemotherapy in Patients With Chemotherapy-Naive Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				NCI				URCC-U3901 NCI-P01-0180, NCT00020657


3.		Phase I/II Chemotherapy with Intracarotid CACP/BLEO in Adults with Unresectable Intracerebral Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 15								MDA-DM-8459 NCI-V85-0016

Last Modified: 11/1/2001 First Published: 11/1/2001


4.		Phase II Randomized Study of High-Dose Metoclopramide for Doxorubicin and Cyclophosphamide-Induced Nausea and Vomiting in Patients With Soft Tisuue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Completed				18 and over				NCI				NCI-83-C-72 NCI-T83-1453

Last Modified: 3/1/1990


5.		Phase II Study of DOX Potentiation with Prochlorperazine in Patients with Advanced Breast Cancer (Summary Last Modified 03/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								SCCC-8944 NCI-V89-0302

Last Modified: 4/27/2007


6.		Phase II Pilot Study of DOX and Prochlorperazine in Patients with Renal Cell Carcinoma (Summary Last Modified 08/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								SCCC-91138 NCI-V92-0061

Last Modified: 8/1/1995


7.		Phase II Study of DOX with the Cellular Efflux Blocking Agent Prochlorperazine in Advanced Lung Cancer (Summary Last Modified 08/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								SCCC-91137 NCI-V92-0062

Last Modified: 5/1/1998


8.		Phase II Study of DOX/Prochlorperazine in Patients with Malignant Mesothelioma (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18				Other				SCCC-9072 NCI-V92-0063

Last Modified: 12/1/1993


9.		Phase II Study of Single-Dose Intravenous Ondansetron/Dexamethasone to Control Acute Vomiting Followed by Oral Dexamethasone/Prochlorperazine to Control Delayed Vomiting in Patients Receiving High-Dose Doxorubicin (Summary Last Modified 12/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Completed				18 and over								MSKCC-93098 NCI-V93-0318

Last Modified: 7/1/1997


10.		Phase I Study of Biochemical Modulation of Carboplatin/Etoposide by Dipyridamole/Prochlorperazine/Cyclosporine in Advanced or Refractory Cancer (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to physiologic 70				NCI				CHNMC-IRB-91149 NCI-V96-1029

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute